These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 25370797

  • 1. A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models.
    Larsson PG, Lakshmikanth T, Laitinen OH, Utorova R, Jacobson S, Oikarinen M, Domsgen E, Koivunen MR, Chaux P, Devard N, Lecouturier V, Almond J, Knip M, Hyöty H, Flodström-Tullberg M.
    Diabetologia; 2015 Feb; 58(2):346-54. PubMed ID: 25370797
    [Abstract] [Full Text] [Related]

  • 2. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes.
    Stone VM, Hankaniemi MM, Svedin E, Sioofy-Khojine A, Oikarinen S, Hyöty H, Laitinen OH, Hytönen VP, Flodström-Tullberg M.
    Diabetologia; 2018 Feb; 61(2):476-481. PubMed ID: 29151123
    [Abstract] [Full Text] [Related]

  • 3. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.
    Hankaniemi MM, Laitinen OH, Stone VM, Sioofy-Khojine A, Määttä JAE, Larsson PG, Marjomäki V, Hyöty H, Flodström-Tullberg M, Hytönen VP.
    Vaccine; 2017 Jun 27; 35(30):3718-3725. PubMed ID: 28579231
    [Abstract] [Full Text] [Related]

  • 4. Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect.
    Stone VM, Butrym M, Hankaniemi MM, Sioofy-Khojine AB, Hytönen VP, Hyöty H, Flodström-Tullberg M.
    Diabetes; 2021 Dec 27; 70(12):2871-2878. PubMed ID: 34497136
    [Abstract] [Full Text] [Related]

  • 5. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
    Hankaniemi MM, Stone VM, Andrejeff T, Heinimäki S, Sioofy-Khojine AB, Marjomäki V, Hyöty H, Blazevic V, Flodström-Tullberg M, Hytönen VP, Laitinen OH.
    Antiviral Res; 2019 Nov 27; 171():104595. PubMed ID: 31491431
    [Abstract] [Full Text] [Related]

  • 6. A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine.
    Hankaniemi MM, Stone VM, Sioofy-Khojine AB, Heinimäki S, Marjomäki V, Hyöty H, Blazevic V, Laitinen OH, Flodström-Tullberg M, Hytönen VP.
    Vaccine; 2019 Sep 20; 37(40):5962-5971. PubMed ID: 31471148
    [Abstract] [Full Text] [Related]

  • 7. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.
    Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, Li D, Jin X, An W, Huang Z.
    Vaccine; 2014 Jul 23; 32(34):4296-303. PubMed ID: 24950363
    [Abstract] [Full Text] [Related]

  • 8. Development of A Neonatal Mouse Model for Coxsackievirus B1 Antiviral Evaluation.
    Yin Z, Wu Y, Zhu R, Xu L, Lin Y, Yang H, Fu W, Huang Q, Zhang D, Wang J, Wang W, Wang Y, Cheng T, Xia N.
    Virol Sin; 2021 Dec 23; 36(6):1575-1584. PubMed ID: 34581960
    [Abstract] [Full Text] [Related]

  • 9. Screening of a new candidate coxsackievirus B1 vaccine strain based on its biological characteristics.
    Zhang M, Xu D, Liu Y, Wang X, Xu L, Gao N, Feng C, Guo W, Ma S.
    Front Microbiol; 2023 Dec 23; 14():1172349. PubMed ID: 37502400
    [Abstract] [Full Text] [Related]

  • 10. Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection.
    Drescher KM, Kono K, Bopegamage S, Carson SD, Tracy S.
    Virology; 2004 Nov 24; 329(2):381-94. PubMed ID: 15518817
    [Abstract] [Full Text] [Related]

  • 11. Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. Childhood Diabetes in Finland (DiMe) Study Group.
    Roivainen M, Knip M, Hyöty H, Kulmala P, Hiltunen M, Vähäsalo P, Hovi T, Akerblom HK.
    J Med Virol; 1998 Sep 24; 56(1):74-8. PubMed ID: 9700636
    [Abstract] [Full Text] [Related]

  • 12. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
    Cai Y, Ku Z, Liu Q, Leng Q, Huang Z.
    Vaccine; 2014 May 01; 32(21):2406-12. PubMed ID: 24657161
    [Abstract] [Full Text] [Related]

  • 13. [A bivalent VP1 gene vaccine against Coxsackie virus B1/B3].
    Wu X, Zhao T, Tian Y.
    Zhonghua Yi Xue Za Zhi; 2001 Apr 25; 81(8):480-4. PubMed ID: 11798923
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
    Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, Li X, Jin J, Xu L, Zhao D, Fan P, An D, Yang P, Lu J, Lv X, Sun B, Xu F, Kong W, Jiang C.
    Hum Vaccin Immunother; 2014 Apr 25; 10(10):2885-95. PubMed ID: 25483672
    [Abstract] [Full Text] [Related]

  • 15. Previous maternal infection protects offspring from enterovirus infection and prevents experimental diabetes development in mice.
    Larsson PG, Lakshmikanth T, Svedin E, King C, Flodström-Tullberg M.
    Diabetologia; 2013 Apr 25; 56(4):867-74. PubMed ID: 23344730
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
    Caine EA, Fuchs J, Das SC, Partidos CD, Osorio JE.
    Viruses; 2015 Nov 17; 7(11):5919-32. PubMed ID: 26593938
    [Abstract] [Full Text] [Related]

  • 17. Coxsackievirus B1-induced chronic inflammatory myopathy: differences in induction of autoantibodies to muscle and nuclear antigens by cloned myopathic and amyopathic viruses.
    Tam PE, Fontana DR, Messner RP.
    J Lab Clin Med; 2003 Sep 17; 142(3):196-204. PubMed ID: 14532908
    [Abstract] [Full Text] [Related]

  • 18. Application of bioinformatics in probe design enables detection of enteroviruses on different taxonomic levels by advanced in situ hybridization technology.
    Laiho JE, Oikarinen S, Oikarinen M, Larsson PG, Stone VM, Hober D, Oberste S, Flodström-Tullberg M, Isola J, Hyöty H.
    J Clin Virol; 2015 Aug 17; 69():165-71. PubMed ID: 26209400
    [Abstract] [Full Text] [Related]

  • 19. Coxsackieviruses and diabetes.
    Ramsingh AI, Chapman N, Tracy S.
    Bioessays; 1997 Sep 17; 19(9):793-800. PubMed ID: 9297970
    [Abstract] [Full Text] [Related]

  • 20. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.
    Fohlman J, Pauksen K, Morein B, Bjare U, Ilbäck NG, Friman G.
    Scand J Infect Dis Suppl; 1993 Sep 17; 88():103-8. PubMed ID: 8390713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.